Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease

Respiratory Medicine

Volumn 102, Issue 7, 2008, Pages 1015-1020

  Minai, Omar A ^a   Sahoo, D ^a   Chapman, J T ^a   Mehta, A C ^a  

^a Allergy   (United States)

Author keywords

Bosentan; Epoprostenol; Pulmonary fibrosis; Pulmonary hypertension; Therapeutics

Indexed keywords

BOSENTAN; PROSTACYCLIN; SILDENAFIL; UNIPROST; VASOACTIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEMODYNAMICS; HUMAN; LUNG FUNCTION; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; WALKING;

ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; EXERCISE TOLERANCE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME; VASODILATOR AGENTS; WALKING;

EID: 44749091490     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.02.002     Document Type: Article

References (27)

1. Simmoneau G., Galie N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 (2004) 5S-12S
2. Nathan S.D., Noble P.W., and Tuder R.M. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 175 (2007) 875-880
3. Naeije R., and Barbera J.A. Pulmonary hypertension associated with COPD. Crit Care 5 (2001) 286-289
4. King T.E., Tooze J.A., Schwarz M.I., et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 164 (2001) 1171-1181
5. Lama V.N., Flaherty K.R., Toews G.B., et al. Prognostic value of desaturation during a 6-min walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 168 (2003) 1084-1090
6. Hallstrand T.S., Boitano L.J., Johnson W.C., et al. The timed walk test as a meaure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 25 (2005) 96-103
7. Bishop J.M., and Cross K.W. Physiological variables and mortality in patients with various categories of chronic respiratory disease. Bull Eur Physiopathol Respir 20 (1984) 495-500
8. Giaid A., Michel R.P., Stewart D.J., Sheppard M., Corrin B., and Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 341 (1993) 1550-1554
9. Trakada G., Nikolaou E., Pouli A., Tsiamita M., and Spiropoulos K. Endothelin-1 levels in interstitial lung disease patients during sleep. Sleep Breath 7 (2003) 111-118
10. Badesch D.B., Abman S.H., Simmoneau G., Rubin L.J., and McLaughlin V.V. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence based clinical practice guidelines. Chest 131 (2007) 1917-1928
11. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Inter Med 132 (2000) 425-434
12. McLaughlin V.V., Genthner D.E., Panella M.M., Hess D.M., and Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 130 (1999) 740-743
13. Olschewski H., Ghofrani H.A., Walmrath D., et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160 (1999) 600-607
14. Collard H.R., Anstrom K.J., Schwarz M.I., and Zisman D.A. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 131 (2007) 897-899
15. Madden B.P., Allenby M., Loke T.-K., and Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vasc Pharmacol 44 (2006) 372-376
16. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 360 (2002) 895-900
17. Egan J.J. New treatments for pulmonary fibrosis?. Lancet 354 (1999) 1839-1840
18. Agusti A.G., and Rodriguez-Roisin R. Effects of pulmonary hypertension on gas exchange. Eur Respir J 6 (1993) 1371-1377
19. McGoon M., Gutterman D., Steen V., et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 14S-34S
20. Yamane K., Miyauchi T., Suzuki N., et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 19 (1992) 1566-1571
21. Sofia M., Mormile M., Faraone S., Alifano M., Carratu P., and Carratu L. Endothelin-1 excretion in urine in active pulmonary sarcoidosis and in other interstitial lung diseases. Sarcoidosis 12 (1995) 118-123
22. Letizia C., Danese A., Reale M.G., et al. Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission. Panminerva Med 43 (2001) 257-261
23. Uguccioni M., Pulsatelli L., Grigolo B., et al. Endothelin-1 in idiopathic pulmonary fibrosis. J Clin Pathol 48 (1995) 330-334
24. Teder P., and Noble P.W. A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 23 (2000) 7-10
25. Stupi A.M., Steen V.D., Owens G.R., et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 29 (1986) 515-524
26. Heresi G.A., and Minai O.A. Lupus-associated pulmonary hypertension: long-term response to vasoactive therapy. Respir Med 101 (2007) 2099-2107
27. Nunes H., Humbert M., Capron F., et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 61 (2006) 68-74